Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer

by St. Jude Children's Research HospitalCredit: Unsplash/CC0 Public DomainFibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The d

Updated on: March 30,2024 0

Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer

by St. Jude Children's Research HospitalCredit: Unsplash/CC0 Public DomainFibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The d

Updated on:March 30,2024 0

AI-based app can help physicians find skin melanoma

by Karin Söderlund,Swedish Research CouncilGraph showing the relationships between the primary care physicians' (PCPs') reported degree of melanoma suspicion, final tumor diagnosis and t

Updated on: March 30,2024 0

AI-based app can help physicians find skin melanoma

by Karin Söderlund,Swedish Research CouncilGraph showing the relationships between the primary care physicians' (PCPs') reported degree of melanoma suspicion, final tumor diagnosis and t

Updated on:March 30,2024 0

Genetically engineered dendritic cells enhance the power of immunotherapy against lung cancer

by Denise Heady,University of California, Los AngelesGraphical Abstract. Credit:Cell Reports Medicine(2024). DOI: 10.1016/j.xcrm.2024.101479A study by researchers at the UCLA Health

Updated on: March 30,2024 0

Genetically engineered dendritic cells enhance the power of immunotherapy against lung cancer

by Denise Heady,University of California, Los AngelesGraphical Abstract. Credit:Cell Reports Medicine(2024). DOI: 10.1016/j.xcrm.2024.101479A study by researchers at the UCLA Health

Updated on:March 30,2024 0

Survival 21 percent a year after ICU discharge for blood cancer patients

by Elana GotkineFor hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months, according to a study published onl

Updated on: March 30,2024 0

Survival 21 percent a year after ICU discharge for blood cancer patients

by Elana GotkineFor hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months, according to a study published onl

Updated on:March 30,2024 0

New bioinformatics tool to identify chromosomal alterations in tumor cells

by University of BarcelonaRepresentative output image generated by QATS in which two toroidal nuclei (in magenta) and four micronuclei (in green) were identified. Credit:Bioinformatics&nbsp

Updated on: March 30,2024 0

New bioinformatics tool to identify chromosomal alterations in tumor cells

by University of BarcelonaRepresentative output image generated by QATS in which two toroidal nuclei (in magenta) and four micronuclei (in green) were identified. Credit:Bioinformatics&nbsp

Updated on:March 30,2024 0

Why do cancer patients lose weight? Study points to elevated lactate levels

byNature Publishing GroupSchematic illustration depicting the signaling cascade downstream of lactate/GPR81 in promoting cancer cachexia. Credit:Nature Metabolism(2024). DOI: 10.1038

Updated on: March 30,2024 0

Why do cancer patients lose weight? Study points to elevated lactate levels

byNature Publishing GroupSchematic illustration depicting the signaling cascade downstream of lactate/GPR81 in promoting cancer cachexia. Credit:Nature Metabolism(2024). DOI: 10.1038

Updated on:March 30,2024 0

Lu(a)minar flow odyssey—using the power of water and light in early leukemia diagnostics

by Polish Academy of SciencesOpto-hydrodynamic tweezers. (a) and (b) Schematic illustrations of the top view and side view of OHT, respectively, along with the major various forces acting on the

Updated on: March 30,2024 0

Lu(a)minar flow odyssey—using the power of water and light in early leukemia diagnostics

by Polish Academy of SciencesOpto-hydrodynamic tweezers. (a) and (b) Schematic illustrations of the top view and side view of OHT, respectively, along with the major various forces acting on the

Updated on:March 30,2024 0

Metalloimmunotherapy: Combination of cisplatin and STING agonist into one molecule boosts cancer immune response

by Science China PressSchematic illustration of the construction of conjugates I and II. Schematic illustration of the combinational effects on tumors of the PtIV-MSA-2 conjugates. The PtIV-MSA-2

Updated on: March 30,2024 0

Metalloimmunotherapy: Combination of cisplatin and STING agonist into one molecule boosts cancer immune response

by Science China PressSchematic illustration of the construction of conjugates I and II. Schematic illustration of the combinational effects on tumors of the PtIV-MSA-2 conjugates. The PtIV-MSA-2

Updated on:March 30,2024 0

Mortality among low-risk differentiated thyroid cancer survivors in the US

by Kathryn Ryan,Mary Ann Liebert, IncFlowchart of the study population. Credit:Thyroid(2023). DOI: 10.1089/thy.2023.0449A new study has shown that overall and cause-specific mortalit

Updated on: March 30,2024 0

Mortality among low-risk differentiated thyroid cancer survivors in the US

by Kathryn Ryan,Mary Ann Liebert, IncFlowchart of the study population. Credit:Thyroid(2023). DOI: 10.1089/thy.2023.0449A new study has shown that overall and cause-specific mortalit

Updated on:March 30,2024 0

New treatment option for prostate cancer shows successful outcomes

by The Reis GroupCredit: CC0 Public DomainA minimally-invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation is effective in treating prostate cancer, according to n

Updated on: March 30,2024 0

New treatment option for prostate cancer shows successful outcomes

by The Reis GroupCredit: CC0 Public DomainA minimally-invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation is effective in treating prostate cancer, according to n

Updated on:March 30,2024 0

Cancer-predisposition variants associated with adverse outcomes in rhabdomyosarcoma

by Molly Chiu,Baylor College of MedicineKaplan-Meier Survival Outcomes of Cancer-Predisposition Variant (CPV) Status on Rhabdomyosarcoma (RMS). Credit:JAMA Network Open(2024). DOI: 1

Updated on: March 30,2024 0

Cancer-predisposition variants associated with adverse outcomes in rhabdomyosarcoma

by Molly Chiu,Baylor College of MedicineKaplan-Meier Survival Outcomes of Cancer-Predisposition Variant (CPV) Status on Rhabdomyosarcoma (RMS). Credit:JAMA Network Open(2024). DOI: 1

Updated on:March 30,2024 0

Clinical trial: Some sarcoma patients improve with T cell immunotherapy

by Julia Evangelou Strait,Washington University School of Medicine in St. LouisCredit: Pixabay from PexelsA clinical trial led by researchers at Washington University School of Medicine in St. L

Updated on: March 30,2024 0

Clinical trial: Some sarcoma patients improve with T cell immunotherapy

by Julia Evangelou Strait,Washington University School of Medicine in St. LouisCredit: Pixabay from PexelsA clinical trial led by researchers at Washington University School of Medicine in St. L

Updated on:March 30,2024 0